Payment overview · 2025
General Payments
$320.33
7 reported records · 4 companies
Healthcare provider profile · identity verified
James Anthony Michail, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GRANADA HILLS, CA · NPI 1760879217
Verified facts
What the public records show
CMS Open Payments records show James Anthony Michail, M.D. received $320.33 in general payments during 2025 across 7 reported records.
Otsuka Pharmaceutical Development & Commercialization, Inc. accounted for 73.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid, Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1247 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $234.97 | 73.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.17 | 12.5% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $27.48 | 8.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.71 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $320.33 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $252.68 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1247 | 151 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1482 | 270 |
| Eliquis | Apixaban | 1247 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 1008 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 992 | 166 |
| Metoprolol Tartrate | Metoprolol Tartrate | 840 | 146 |
| Gabapentin | Gabapentin | 742 | 136 |
| Tamsulosin Hcl | Tamsulosin Hcl | 587 | 111 |
| Metformin Hcl | Metformin Hcl | 575 | 118 |
| Furosemide | Furosemide | 540 | 111 |
| Famotidine | Famotidine | 510 | 99 |
| Potassium Chloride | Potassium Chloride | 456 | 88 |
| Quetiapine Fumarate | Quetiapine Fumarate | 442 | 69 |
| Losartan Potassium | Losartan Potassium | 441 | 106 |
| Clopidogrel | Clopidogrel Bisulfate | 429 | 75 |
| Hydralazine Hcl | Hydralazine Hcl | 406 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 400 | 103 |
| Lisinopril | Lisinopril | 393 | 76 |
| Carvedilol | Carvedilol | 350 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 342 | 68 |
| Mirtazapine | Mirtazapine | 315 | 64 |
| Omeprazole | Omeprazole | 303 | 74 |
| Entresto | Sacubitril/Valsartan | 276 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 65 |
| Finasteride | Finasteride | 241 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 46 |
| Allopurinol | Allopurinol | 215 | 47 |
| Divalproex Sodium | Divalproex Sodium | 201 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 192 | 31 |
| Latanoprost | Latanoprost | 187 | 41 |
| Levetiracetam | Levetiracetam | 185 | 31 |
| Bumetanide | Bumetanide | 171 | 35 |
| Sertraline Hcl | Sertraline Hcl | 163 | 32 |
| Simvastatin | Simvastatin | 151 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 26 |
| Trazodone Hcl | Trazodone Hcl | 145 | 39 |
| Januvia | Sitagliptin Phosphate | 144 | 16 |
| Risperidone | Risperidone | 141 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 139 | 77 |
| Olanzapine | Olanzapine | 134 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 133 | 21 |
| Clonidine Hcl | Clonidine Hcl | 131 | 44 |
| Montelukast Sodium | Montelukast Sodium | 129 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 21 |
| Timolol Maleate | Timolol Maleate | 122 | 20 |
| Glipizide | Glipizide | 121 | 22 |
| Donepezil Hcl | Donepezil Hcl | 119 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 25 |
| Midodrine Hcl | Midodrine Hcl | 118 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 108 | 24 |
| Jardiance | Empagliflozin | 108 | 24 |
| Atenolol | Atenolol | 107 | 19 |
| Digoxin | Digoxin | 105 | 17 |
| Buspirone Hcl | Buspirone Hcl | 100 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 96 | 26 |
| Baclofen | Baclofen | 92 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 14 |
| Memantine Hcl | Memantine Hcl | 88 | 17 |
| Xarelto | Rivaroxaban | 88 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 85 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | 15 |
| Lorazepam | Lorazepam | 82 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 40 |
| Cephalexin | Cephalexin | 78 | 58 |
| Brimonidine Tartrate | Brimonidine Tartrate | 77 | 12 |
| Lubiprostone | Lubiprostone | 76 | 15 |
| Prednisone | Prednisone | 76 | 36 |
| Ezetimibe | Ezetimibe | 75 | 13 |
| Alprazolam | Alprazolam | 73 | 24 |
| Nifedipine Er | Nifedipine | 73 | 23 |
| Cefdinir | Cefdinir | 65 | 48 |
| Insulin Aspart Flexpen | Insulin Aspart | 65 | 15 |
| Tradjenta | Linagliptin | 65 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | suppressed |
| Valsartan | Valsartan | 60 | 11 |
| Azithromycin | Azithromycin | 59 | 49 |
| Clonidine | Clonidine | 59 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 13 |
| Sodium Chloride | 0.9 % Sodium Chloride | 57 | 16 |
| Sevelamer Carbonate | Sevelamer Carbonate | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 52 | 13 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 51 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 13 |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Clonazepam | Clonazepam | 49 | 12 |
| Lidocaine | Lidocaine | 49 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 48 | 25 |
| Benazepril Hcl | Benazepril Hcl | 47 | suppressed |
| Novolog Flexpen | Insulin Aspart | 47 | suppressed |
| Carbamazepine | Carbamazepine | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 46 | 12 |
| Rexulti | Brexpiprazole | 46 | suppressed |
| Glimepiride | Glimepiride | 45 | suppressed |
| Permethrin | Permethrin | 45 | 34 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 43 | 20 |
| Creon | Lipase/Protease/Amylase | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Vascepa | Icosapent Ethyl | 42 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 41 | 19 |
| Lansoprazole | Lansoprazole | 41 | 11 |
| Cyclosporine | Cyclosporine | 40 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 37 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 26 |
| Levofloxacin | Levofloxacin | 35 | 31 |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 33 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 33 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Dutasteride | Dutasteride | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 14 |
| Lumigan | Bimatoprost | 32 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 16 |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 15 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 18 |
| Brilinta | Ticagrelor | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Lactulose | Lactulose | 29 | 11 |
| Meloxicam | Meloxicam | 29 | 22 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 27 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Nystatin | Nystatin | 25 | 17 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 25 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Zileuton Er | Zileuton | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Ivermectin | Ivermectin | 23 | 21 |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Erythromycin | Erythromycin Base | 22 | 15 |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Pentasa | Mesalamine | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Ertapenem | Ertapenem Sodium | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 21 | suppressed |
| Alvesco | Ciclesonide | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 20 | 16 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 19 | 11 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Spinosad | Spinosad | 16 | 14 |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Librax | Chlordiazepoxide/Clidinium Br | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Rhopressa | Netarsudil Mesylate | 14 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Prozac | Fluoxetine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Miebo | Perfluorohexyloctane/Pf | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Verquvo | Vericiguat | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Brinzolamide | Brinzolamide | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $320.33 · 7 records | Otsuka Pharmaceutical Development & Commercialization, Inc. | PAXLOVID, REXULTI, VYNDAQEL, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error